437 related articles for article (PubMed ID: 18809617)
21. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.
von Plessen C; Bergman B; Andresen O; Bremnes RM; Sundstrom S; Gilleryd M; Stephens R; Vilsvik J; Aasebo U; Sorenson S
Br J Cancer; 2006 Oct; 95(8):966-73. PubMed ID: 17047644
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.
Butts CA; Ding K; Seymour L; Twumasi-Ankrah P; Graham B; Gandara D; Johnson DH; Kesler KA; Green M; Vincent M; Cormier Y; Goss G; Findlay B; Johnston M; Tsao MS; Shepherd FA
J Clin Oncol; 2010 Jan; 28(1):29-34. PubMed ID: 19933915
[TBL] [Abstract][Full Text] [Related]
23. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.
Brown J; Thorpe H; Napp V; Fairlamb DJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG; Stephens RJ; Waller D; West P; Peake MD
J Clin Oncol; 2005 Oct; 23(30):7417-27. PubMed ID: 16157935
[TBL] [Abstract][Full Text] [Related]
24. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.
Park SY; Lee JG; Kim J; Byun GE; Bae MK; Lee CY; Kim DJ; Chung KY
J Cardiothorac Surg; 2013 Jun; 8():151. PubMed ID: 23759129
[TBL] [Abstract][Full Text] [Related]
26. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
Arriagada R; Bergman B; Dunant A; Le Chevalier T; Pignon JP; Vansteenkiste J;
N Engl J Med; 2004 Jan; 350(4):351-60. PubMed ID: 14736927
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
Waller D; Peake MD; Stephens RJ; Gower NH; Milroy R; Parmar MK; Rudd RM; Spiro SG
Eur J Cardiothorac Surg; 2004 Jul; 26(1):173-82. PubMed ID: 15200998
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.
Saka H; Kitagawa C; Ichinose Y; Takenoyama M; Ibata H; Kato T; Takami K; Yamashita M; Maeda T; Takeo S; Ueda H; Okabayashi K; Nagashima S; Oka T; Kouso H; Fukuyama S; Yoshimoto K; Shimokawa M; Saito AM; Ito S
Trials; 2017 Sep; 18(1):429. PubMed ID: 28915900
[TBL] [Abstract][Full Text] [Related]
31. Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer.
Mohan A; Singh P; Kumar S; Mohan C; Pathak AK; Pandey RM; Guleria R
Asian Pac J Cancer Prev; 2008; 9(4):557-62. PubMed ID: 19256738
[TBL] [Abstract][Full Text] [Related]
32. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
Shukuya T; Takahashi T; Tamiya A; Ono A; Igawa S; Tsuya A; Nakamura Y; Murakami H; Naito T; Kaira K; Endo M; Yamamoto N
Jpn J Clin Oncol; 2009 Mar; 39(3):158-62. PubMed ID: 19139038
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
35. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
[TBL] [Abstract][Full Text] [Related]
36. [Effectiveness of adjuvant chemotherapy in patient with early stages of non-small cell lung cancer depending on proliferation index of tumor].
Kolesnik AP
Lik Sprava; 2014; (1-2):110-7. PubMed ID: 24908971
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant carboplatin-based chemotherapy in resected stage IIIA-N2 non-small cell lung cancer.
Ou W; Sun HB; Ye X; Zhang BB; Yang H; Fang Q; Li P; Wang SY
J Thorac Oncol; 2010 Jul; 5(7):1033-41. PubMed ID: 20502361
[TBL] [Abstract][Full Text] [Related]
38. Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.
Kreuter M; Vansteenkiste J; Herth FJ; Fischer JR; Eberhardt W; Zuna I; Reinmuth N; Griesinger F; Thomas M;
Respiration; 2014; 87(3):204-10. PubMed ID: 24192055
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
